UPDATED: Rubius chief lays out the first human data on their lead red cell drug in a comeback play. And the stock skyrockets
Rubius $RUBY CEO Pablo Cagnoni is facing a critical and closely-watched test today.
Almost exactly a year after watching the biotech’s shares routed after dumping their lead program, Cagnoni offered me a look at the first cut of the human data from their current lead cancer drug program for their red blood cell therapeutics platform. And while all the numbers are small and the early data just a snapshot of what’s to come, it could prove a tough sell.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.